Arcellx, Kite aim to keep chipping away at Carvykti advantage with new multiple myeloma data at ASH

SAN DIEGO — Arcellx raised the curtain on the CAR-T data it will present on Monday at the American Society of Hematology conference as it readies a multiyear plan to take on J&J and Legend Biotech’s Carvykti, as well as Bristol Myers Squibb’s Abecma.

Data from a Phase I multiple…
Click here to view original post